We are at a critical inflection point in our efforts to eliminate health inequities. Across the conditions that our medicines treat, there are significant barriers for patients at every point in the care journey. Often, these unjust and avoidable barriers are the result of systemic racism, and cannot be overcome by individual behavior change alone.
At Genentech, we prioritize health equity in everything we do – from clinical study design to our access/policy priorities to our philanthropic investments. That’s why, in 2019, we launched the Genentech Health Equity Innovation Fund to catalyze efforts to eliminate inequities in patient health outcomes. Through the 2024 Innovation Fund, we are seeking to fund teams focused on measurably and sustainably closing racial/ethnic inequities in healthcare to create a future where:
Click the links below to jump to the section you wish to view:
Below are the high-level outcomes we invited applications for, and examples of projects that would advance progress towards those outcomes. Note: These examples should not be considered an exhaustive list of the kinds of programs Genentech will consider.
OUTCOME | PROGRAM EXAMPLES |
---|---|
1) Increasing rates of screening and diagnosis while promoting care continuity |
|
2) Widening the capacity and accessibility of specialty care services and linkages to critical non-clinical services |
|
3) Enhancing the quality, safety, and experience of care for patients and promoting adherence and satisfaction |
|
4) Shifting institutional and system-wide policies and practices to deepen long-term accountability for equity |
|
5) Increased training program capacity and matriculation/completion rates for practitioners/clinicians* who are underrepresented in medicine and clinical care delivery (with a priority on specialty care) *Practitioners/clinicians may include a variety of healthcare practitioners that support a multi-disciplinary care team (e.g,. specialty care, community health workers, nurse practitioners, and other allied healthcare professionals) |
|
6) Increased retention, reduced turnover and increased satisfaction of physicians, researchers* and clinical support staff *Researchers may include clinician scientists, clinical trial coordinators and more |
|
For the 2024 Innovation Fund, we sought applications that bring a systemic lens to this work, cutting across multiple outcomes with a focus on root causes. We were specifically interested in seeking applications that address inequities in patient outcomes and healthcare workforce experiences in the following areas:
Initial applications for the 2024 Innovation Fund are now closed. Those who applied will be notified by July 1 2024 about whether they will be invited to submit a full application or if their application has been denied. Please visit funding.gene.com to learn about our open funding opportunities.
We brought together the following Genentech advisors to support the aims of the Innovation Fund by providing strategic input and guidance on the RFP process, reviewing and providing input on high-potential applications, and informing the design of the Innovation Fund Learning Cohort.
Sonali Chopra, MPH, MBA
Executive Director, Alliance and Advocacy Relations Team
Rajni Dronamraju
Senior Director and Head of Giving and Social Impact
Jennifer Kim, PharmD
US Head Ophthalmology Squad Leader
Shalini V. Mohan, MD
Head, Health Equity and Inclusive Research, U.S. Medical Affairs
Nicole Richie, PhD
Vice President, Portfolio & People Leader
Suzie Tam Porter, JD
Vice President, Channel and Contract Management
Erica Taylor, PhD
Chief Marketing Officer
Pierre Theodore, MD
Head of Patient Inclusion and Health Equity